Evidence map›Paper›PMID 36264673›Full record

ReviewCancer cytopathology2023

Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates.

Richard L Cantley, Xiaoming Wang, Zachery R Reichert, Arul M Chinnaiyan, Rahul Mannan, Xuhong Cao, Daniel E Spratt, Ulka N Vaishampayan, Joshi J Alumkal, Todd M Morgan and 4 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer cytopathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Richard L CantleyDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.ORCID 0000-0002-6564-3889
Xiaoming WangDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Zachery R ReichertRogel Cancer Center, Michigan Medicine, Ann Arbor, Michigan, USA.
Arul M ChinnaiyanMichigan Center for Translational Pathology, Ann Arbor, Michigan, USA.
Rahul MannanDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Xuhong CaoDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Daniel E SprattDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
Ulka N VaishampayanRogel Cancer Center, Michigan Medicine, Ann Arbor, Michigan, USA.
Joshi J AlumkalRogel Cancer Center, Michigan Medicine, Ann Arbor, Michigan, USA.
Todd M MorganRogel Cancer Center, Michigan Medicine, Ann Arbor, Michigan, USA.
Ganesh PalapattuRogel Cancer Center, Michigan Medicine, Ann Arbor, Michigan, USA.
Matthew S DavenportDepartment of Urology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Liron PantanowitzDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.ORCID 0000-0001-8182-5503
Rohit MehraDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
University of Michigan · USHoward Hughes Medical Institute · USUniversity Hospitals Seidman Cancer Center · US

Funding

Tissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu · 2014 to 2026
$27.6M
Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancerU01CA214170 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2016 to 2021
$3.3M
EDRN U01CA214170Michigan Prostate SPORE P50CA186786NCI NIH HHS P50 CA186786NCI NIH HHS U01 CA214170
6 · The paper itself

Abstract

introductionThe diagnosis of metastatic prostatic cancer (MPC) by fine needle aspiration (FNA) can usually be rendered by typical cytomorphologic and immunohistochemical (IHC) features. However, MPC diagnosis may be complicated by transformation to atypical phenotypes such as small cell carcinoma, typically under pressure from androgen deprivation therapy (ADT). Predictive and prognostic biomarkers can also be assessed by IHC. This study illustrates how careful assessment of cytologic and biomarker features may provide therapeutic and prognostic information in MPC.

designWe reviewed our anatomic pathology archives for MPC diagnosed by FNA from January 2014 to June 2021. Clinical histories, cytology slides, and cell blocks were reviewed. Extensive IHC biomarker workup was performed, including markers of prostate lineage, cell-cycle dysfunction, Ki-67, neuroendocrine markers, PDL1, and androgen receptor splice variant 7. Cases were reclassified into three categories: conventional type, intermediary type, and high-grade neuroendocrine carcinoma (HGNC).

resultsEighteen patients were identified. Twelve had conventional MPC, including six of six ADT-naive patients. Six of twelve (50%) with prior ADT were reclassified as intermediary or HGNC. Four intermediary cases included two with squamous differentiation and two with pro-proliferative features. Two HGNC cases had typical small cell carcinoma cytomorphology. Expression of PDL1 was identified in two cases and ARv7 in three cases. Five of five intermediary and HGNC patients died of disease versus six of eleven with with conventional type.

conclusionsAggressive cytomorphologic variants were commonly identified in patients with prior ADT. Identification of nonconventional cytomorphology and increased proliferation can provide important prognostic information. Recognition of these changes is important for an accurate diagnosis, and the identification of high-grade variants can affect therapeutic decision-making. Clinically actionable biomarkers such as PDL1 and ARv7 can be assessed by IHC.

Indexed as

Carcinoma, NeuroendocrineCarcinoma, Small CellLung NeoplasmsProstatic NeoplasmsSmall Cell Lung CarcinomaAndrogen AntagonistsBiomarkersBiopsy, Fine-NeedleHumansMaleAndrogen AntagonistsBiomarkersandrogen receptor (AR)cytopathologyfine needle aspirationneuroendocrineprostate cancersmall cell carcinomatransdifferentiation

Identifiers

PMID36264673
PMCPMC10092797
OpenAlexW4306888812

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.